These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2055655)

  • 41. Anti-inflammatory and antimicrobial effects of nanocatechin in a chronic bacterial prostatitis rat model.
    Yoon BI; Ha US; Sohn DW; Lee SJ; Kim HW; Han CH; Lee CB; Cho YH
    J Infect Chemother; 2011 Apr; 17(2):189-94. PubMed ID: 20694569
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of a Stewardship-Initiated Restriction on Empirical Use of Ciprofloxacin on Nonsusceptibility of Escherichia coli Urinary Isolates to Ciprofloxacin.
    O'Brien KA; Zhang J; Mauldin PD; Gomez J; Hurst JM; Sean Boger M; Bosso JA
    Pharmacotherapy; 2015 May; 35(5):464-9. PubMed ID: 26011139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study.
    Bundrick W; Heron SP; Ray P; Schiff WM; Tennenberg AM; Wiesinger BA; Wright PA; Wu SC; Zadeikis N; Kahn JB
    Urology; 2003 Sep; 62(3):537-41. PubMed ID: 12946763
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fleroxacin (Ro 23-6240) distribution in canine prostatic tissue and fluids.
    Gasser TC; Graversen PH; Madsen PO
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1010-3. PubMed ID: 3116916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin.
    Schaeffer AJ; Darras FS
    J Urol; 1990 Sep; 144(3):690-3. PubMed ID: 2201796
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Ciprofloxacin in the treatment of chronic bacterial prostatitis].
    Trapeznikova MF; Savitskaia KI; al-Suri A; Nekhorosheva AG; Abramian NS; Nasonov VN
    Urol Nefrol (Mosk); 1995; (5):20-3. PubMed ID: 8571477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trimethoprim resistance of Escherichia coli in outpatients in Finland after ten years' use of plain trimethoprim.
    Huovinen P; Renkonen OV; Pulkkinen L; Sunila R; Grönroos P; Klossner ML; Virtanen S; Toivanen P
    J Antimicrob Chemother; 1985 Oct; 16(4):435-41. PubMed ID: 2999058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections.
    Ceran N; Mert D; Kocdogan FY; Erdem I; Adalati R; Ozyurek S; Goktas P
    J Infect Chemother; 2010 Dec; 16(6):424-30. PubMed ID: 20585969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimization of the use of ciprofloxacin.
    Aubert G; Carricajo A; Fonsale N; Vautrin AC
    Pathol Biol (Paris); 2009 May; 57(3):236-9. PubMed ID: 18328635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of the comparability of CLSI, EUCAST and Stokes antimicrobial susceptibility profiles for Escherichia coli uropathogenic isolates.
    O'Halloran C; Walsh N; O'Grady MC; Barry L; Hooton C; Corcoran GD; Lucey B
    Br J Biomed Sci; 2018 Jan; 75(1):24-29. PubMed ID: 29210602
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity of difloxacin against canine bacterial isolates.
    van den Hoven R; Wagenaar JA; Walker RD
    J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of chronic bacterial prostatitis.
    Hanus PM; Danziger LH
    Clin Pharm; 1984; 3(1):49-55. PubMed ID: 6365416
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Five-Year Antimicrobial Resistance Patterns of Urinary Escherichia coli at an Australian Tertiary Hospital: Time Series Analyses of Prevalence Data.
    Fasugba O; Mitchell BG; Mnatzaganian G; Das A; Collignon P; Gardner A
    PLoS One; 2016; 11(10):e0164306. PubMed ID: 27711250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of pH on activity of trimethoprim, fosfomycin, amikacin, colistin and ertapenem in human urine.
    Burian A; Erdogan Z; Jandrisits C; Zeitlinger M
    Pharmacology; 2012; 90(5-6):281-7. PubMed ID: 23037005
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis.
    Fox MT; Melia MT; Same RG; Conley AT; Tamma PD
    Am J Med; 2017 Jul; 130(7):842-845. PubMed ID: 28216442
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of ciprofloxacin compared to trimethoprim-sulfamethoxazole against Campylobacter spp., Shigella spp. and Enterotoxigenic Escherichia coli causing travellers' diarrhea in Egypt.
    Mikhail IA; Bourgeois AL; Hyams KC; Podgore JK; Lissner CR; Walz S
    Scand J Infect Dis; 1987; 19(4):479-81. PubMed ID: 3313681
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Basic patient characteristics predict antimicrobial resistance in E. coli from urinary tract specimens: a retrospective cohort analysis of 5246 urine samples.
    Erb S; Frei R; Tschudin Sutter S; Egli A; Dangel M; Bonkat G; Widmer AF
    Swiss Med Wkly; 2018 Nov; 148():w14660. PubMed ID: 30440065
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of glucose added urine on the in vitro antimicrobial activity of various antibiotics.
    Gönüllü N; Küçükbasmaci O; Büyükbaba-Boral O; Anğ-Küçüker M
    Indian J Med Res; 2008 Nov; 128(5):663-5. PubMed ID: 19179689
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The changing pattern of antimicrobial resistance within 42,033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999-2009.
    Cullen IM; Manecksha RP; McCullagh E; Ahmad S; O'Kelly F; Flynn RJ; McDermott T; Murphy P; Grainger R; Fennell JP; Thornhill JA
    BJU Int; 2012 Apr; 109(8):1198-206. PubMed ID: 21883861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.